
Sol-Gel Investor Relations Material
Latest events

Q2 2025
14 Aug, 2025

Q1 2025
23 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sol-Gel Technologies Ltd
Access all reports
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. The company offers Phase 5 (clobex), a prescription liquid medication designed to selectively target specific classes of dendritic cells that initiate the immune response. Its smevetch is a topical compounded drug that contains tacrolimus and dexamethasone. The company was formerly known as Silex Platform Limited and changed its name to Sol-Gel Technologies Ltd. in June 2010. Sol-Gel Technologies Ltd. is based in London, the United Kingdom.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SLGL
Country
🇺🇸 United States